Introduction {#j_jomb-2016-0002_s_001}
============

Inflammatory bowel disease (IBD) is defined as an idiopathic and chronic intestinal inflammation. Studies show that IBD is a multifactorial disease ([@j_jomb-2016-0002_ref_001], [@j_jomb-2016-0002_ref_002]). It develops in genetically susceptible individuals due to the influence of environmental factors ([@j_jomb-2016-0002_ref_003], [@j_jomb-2016-0002_ref_004]). IBD has two main forms, ulcerative colitis (UC) and Crohn's disease (CD). UC is characterized by inflammation that is limited to the colon. By contrast, CD involves any part of the gastrointestinal tract from the mouth to the anus--most commonly the terminal ileum. Reactive oxygen species (ROS) are free radicals that can attack and damage almost every molecule found in living cells, including proteins, carbohydrates, lipids, and DNA. For this reason, their production is normally tightly controlled. In recent years, increasing attention has been given to the role of reactive oxygen metabolites (ROMs) in the pathogenesis of IBD ([@j_jomb-2016-0002_ref_005]--[@j_jomb-2016-0002_ref_008]).

Among the most important defenses against ROS are the superoxide dismutase (SOD) and catalase (CAT) enzymes. Superoxide dismutase 1 (cytosolic Cu/ZnSOD; SOD1; OMIM: 147450) is the major intracellular SOD ([@j_jomb-2016-0002_ref_009]). It catalyzes the dismutation of the toxic superoxide to hydrogen peroxide and molecular oxygen. The human *SOD1* is 9,309 bp in length on chromosome 21q22.11 and consists of five exons interrupted by four introns ([@j_jomb-2016-0002_ref_010]). A genetic polymorphism of A251G (rs2070424) is located in intron 3 of the *SOD1* gene. The association between the *SOD1* A251G polymorphism and several multifactorial diseases has been reported ([@j_jomb-2016-0002_ref_011]--[@j_jomb-2016-0002_ref_016]).

Catalase (CAT; OMIM: 115500) is an antioxidant enzyme responsible for hydrogen peroxide (H~2~O~2~) conversion into oxygen and water. Its gene is located on chromosome 11p13, 34 kb long and is split into 13 exons ([@j_jomb-2016-0002_ref_017]). A C/T polymorphism located 262 bp upstream to the *CAT* transcription site (C-262T, rs1001179) has been described ([@j_jomb-2016-0002_ref_018]). The T allele is associated with lower levels of red blood cell CAT activity ([@j_jomb-2016-0002_ref_018], [@j_jomb-2016-0002_ref_019]) which may increase the risk of oxidative stress. Several studies investigated the association between *CAT* C-262T polymorphism and multifactorial traits ([@j_jomb-2016-0002_ref_020]--[@j_jomb-2016-0002_ref_025]).

Considering that it is well established that IBD is an inflammatory condition influenced by oxidative stress ([@j_jomb-2016-0002_ref_006]--[@j_jomb-2016-0002_ref_008]), it is hypothesized that the *CAT* C-262T and *SOD1* A215G polymorphisms may affect the risk of UC. Therefore, the present case-control study was carried out.

Materials and Methods {#j_jomb-2016-0002_s_002}
=====================

Participants {#j_jomb-2016-0002_s_002_s001}
------------

A total of 96 UC patients (46 males and 50 females) and 186 healthy controls (67 males and 119 females) were included in this case-control study. The controls and patients were sex matched (P=0.71), but there was a significant difference in mean age between the patients (SD: 36.4±12.8) and controls (SD: 49.9±9.0) so they were not matched (P\<0.001). Based on the several studies investigating numerous genetic polymorphisms, it is concluded that the Iranian population is a heterogeneous population ([@j_jomb-2016-0002_ref_026]--[@j_jomb-2016-0002_ref_028]). Also, it has been reported that the allelic frequency of the *CAT* C-262T and *SOD1* A251G polymorphisms is influenced by ethnicity ([@j_jomb-2016-0002_ref_021], [@j_jomb-2016-0002_ref_025], [@j_jomb-2016-0002_ref_028], also see: [<http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2070424>]{.ul}, and [<http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1001179>]{.ul}). Taken together, our patients and controls were selected among Persian (Caucasian) Muslims living in Shiraz (Fars province, south-west Iran). Informed consent was obtained from each subject before the study. This study was approved by the Shiraz University ethics committee.

Genotyping {#j_jomb-2016-0002_s_002_s002}
----------

Blood samples were obtained from patients and controls. Immediately after collection, whole blood was stored at --20 °C until use. Genomic DNA for PCR was isolated from whole blood using the thawed blood samples. Genotypic analysis for the *CAT* C-262T and *SOD1* A251G polymorphisms was determined as described previously ([@j_jomb-2016-0002_ref_011], [@j_jomb-2016-0002_ref_022]).

Statistical analysis {#j_jomb-2016-0002_s_002_s003}
--------------------

For the control group, the observed frequencies of the genotypes in both polymorphisms were assessed for Hardy--Weinberg equilibrium using the χ^2^ statistic. The odds ratio (OR) and 95% confidence intervals (CIs) were calculated to estimate the strength of the association between polymorphisms and disease. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) (version 11.5). A probability of P\<0.05 was considered statistically significant.

Results {#j_jomb-2016-0002_s_003}
-------

[*Table I*](#j_jomb-2016-0002_tab_001){ref-type="table"} shows the prevalence of the genotypes of *SOD1* A251G polymorphism in IBD patients and healthy control subjects. Hardy--Weinberg equilibrium was determined. The distribution of genotypic frequencies of *SOD1* A251G polymorphism was in Hardy--Weinberg equilibrium in the control group (χ^2^=0.03 df=1, P=0.851). There was no significant association between the AG+GG genotypes (vs. AA genotype) and risk of UC (OR=0.45, 95% CI: 0.17-1.14, P= 0.093). However, after adjusting for age and gender, a significant association was observed (OR=0.29, 95% CI: 0.10--0.86, P=0.025). This means that the G allele decreases the risk of UC and thus has a protective role.

###### 

Risk of ulcerative colitis associated with SOD1 A251G and CAT C-262T genetic polymorphisms.

  Genotypes                   Controls   Cases   OR     95% CI       P       OR[\*](#j_jomb-2016-0002_fn_001){ref-type="table-fn"}   95% CI       P
  --------------------------- ---------- ------- ------ ------------ ------- ------------------------------------------------------- ------------ -------
  *SOD1* A251G polymorphism                                                                                                                       
  AA                          162        90      1.0    --           --      --                                                      --           --
  AG                          23         6       0.47   0.18--1.19   0.113   0.30                                                    0.10--0.89   0.031
  GG                          1          0       --     --           --      --                                                      --           --
  AG+GG                       24         6       0.45   0.17--1.14   0.093   0.29                                                    0.10--0.86   0.025
  *CAT* C-262T polymorphism                                                                                                                       
  CC                          107        63      1.0    --           --      1.0                                                     --           --
  CT                          79         32      0.76   0.45--1.28   0.314   0.83                                                    0.45--1.53   0.557
  TT                          8          1       0.21   0.02--1.73   0.148   0.54                                                    0.06--4.76   0.586
  CT+TT                       79         33      0.70   0.42--1.18   0.189   0.81                                                    0.44--1.48   0.499

Adjusted OR for age and gender.

[*Table I*](#j_jomb-2016-0002_tab_001){ref-type="table"} also shows the frequency of the genotypes of *CAT* C-262T polymorphism in the patients and healthy control subjects. The distribution of genotypic frequencies of *CAT* C-262T polymorphism was in Hardy--Weinberg equilibrium in the control group (χ^2^=1.97, df=1, P=0.158). Our statistical analysis revealed that this polymorphism did not associate with the risk of UC before and/or after adjusting for age and gender ([*Table I*](#j_jomb-2016-0002_tab_001){ref-type="table"}).

Discussion {#j_jomb-2016-0002_s_004}
==========

Our present study has indicated that there is a significant association between the AG+GG genotypes of *SOD1* gene and the risk of UC ([*Table I*](#j_jomb-2016-0002_tab_001){ref-type="table"}). The AG+GG genotypes, therefore, reduce the risk of UC. Further, the AG+GG genotypes seem to play a protective role and thus decrease the risk of UC. To our best knowledge, no studies have investigated the association of *SOD1* A215G polymorphism and the risk of UC. The *SOD1* A215G polymorphism has been found to be associated with several diseases either as a risk factor ([@j_jomb-2016-0002_ref_011]) or as a protective factor ([@j_jomb-2016-0002_ref_012]).

As mentioned in the Introduction section, studies have shown that oxidative stress plays an important role in the development of IBD ([@j_jomb-2016-0002_ref_006]--[@j_jomb-2016-0002_ref_008]). The genetic variation of C-262T in the *CAT* gene is a functional polymorphism ([@j_jomb-2016-0002_ref_018]). There is evidence that the T allele is associated with a lower expression level of the gene ([@j_jomb-2016-0002_ref_018], [@j_jomb-2016-0002_ref_019]). Taken together, it is hypothesized that this allele may increase the risk of UC. However, our present findings do not support the hypothesis ([*Table I*](#j_jomb-2016-0002_tab_001){ref-type="table"}). Only one published study investigated the association between the *CAT* C-262T polymorphism and susceptibility to UC ([@j_jomb-2016-0002_ref_029]). In that study, the authors reported that the CT genotype of the *CAT* C-262T polymorphism increased the risk of IBD. Our present findings are not consistent with the abovementioned report. As strongly recommended by STrengthening the REporting of Genetic Association studies (STREGA), the observed frequencies of the genotypes in control group should show no significant deviation from the expected values based on the Hardy-Weinberg equilibrium ([@j_jomb-2016-0002_ref_030], [@j_jomb-2016-0002_ref_031]). However, in the study of Khodayari et al. ([@j_jomb-2016-0002_ref_029]), although the CT genotype was observed in 69.2 percent of control persons, there was no healthy control subject having the TT genotype; therefore, it is worthwhile to consider that there is significant difference between the observed genotypic frequencies and the expected ones based on the Hardy--Weinberg equilibrium (P\<0.001). It is suggested that errors in the genotyping procedures may have occurred in these situations. Taken together, the results of previous study should be interpreted with caution.

The three main limitations of our current study were the limited number of samples, the non-matching of age between cases and controls, and the fact that we studied only one polymorphism for *CAT* and *SOD1* genes. There are several other single nucleotide polymorphisms for these genes in humans, which were not studied in the present work. Simultaneous study of these polymorphisms (including the haplotype ana lysis) should be further researched. Further studies are recommended for more defensive conclusions.
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